NCT05613452招募中2 期
Prospective Phase II Clinical Study of Carbon Ion Beam Stereotactic Radiotherapy for Peripheral Type Early-stage Non-small Cell Lung Cancer
Shanghai Proton and Heavy Ion Center1 个研究点 分布在 1 个国家目标入组 43 人开始时间: 2024年9月29日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 43
- 试验地点
- 1
- 主要终点
- disease progression-free survival rate
研究概览
简要总结
To investigate the efficacy of carbon ion therapy for stage Ia-IIa primary peripheral non-small cell lung cancer (NSCLC). The primary endpoint was progression-free survival (PFS), and the secondary endpoint was local control rate, overall survival (OS) and toxicities.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Between the ages of 18 and
- •ECOG general status score of 0-2 .
- •Primary non-small cell lung cancer (NSCLC) confirmed by histology or cytological pathology, T1-2N0M0, stage Ia-IIa (AJCC/UICC 8th edition).
- •The location of the tumor belongs to the peripheral type defined in this study (2cm and beyond (≥2cm) from the esophagus, main bronchial tree, spinal cord, heart, great blood vessels, brachial plexus and stomach, and 1cm and beyond (≥1cm) from the chest wall).
- •Medically inoperable, or patient refuses surgery.
- •Adequate organ function: 1). Blood function: absolute neutrophil count (ANC) ≥1.5 x 109/L, platelet count ≥80 x 109/L, hemoglobin ≥9 g/dL 2). Lung function: FEV1>25%, DLCO>25% 3). Cardiac function: no serious pulmonary hypertension, cardiovascular and cerebrovascular diseases, peripheral vascular diseases, serious chronic heart disease and other complications that may affect radiotherapy.4). Adequate liver function: total bilirubin <1.5 times the upper limit of normal value, and AST, ALT<2 times the upper limit of normal value. 5). Adequate renal function: serum creatinine ≤1.5 times the upper limit of normal or calculated creatinine clearance ≥50 ml /min, and urinary protein <2+. Patients with a baseline urinary protein level of 2+ or more should have a 24-hour urine collection and evidence of a 24-hour urinary protein level of 1g or less.
- •Sign the informed consent.
排除标准
- •Multiple primary tumors.
- •Patient fails to comply with the treatment protocol.
- •Complicated with other malignant tumors that have not been controlled.
- •Patient whose particle radiotherapy plan cannot meet the minimum target dose coverage and dose volume limitation requirements, or cannot meet the dose constrains of normal tissue or organs.
- •Chest radiation therapy or radioactive particle implantation history.
- •Cardiac pacemakers or other internal metal prosthesis implants that may be affected by high-energy radiation or may affect the dose distribution to the radiation target area.
- •Pregnancy (confirmed by serum or urine β-HCG test) or lactation period.
- •HIV positive. Hepatitis virus replication phase, need to receive antiviral therapy, but because of concomitant disease cannot receive antiviral therapy. Active stage of syphilis.
- •A history of mental illness may hinder the completion of treatment.
- •With serious comorbidity that may interfere with radiotherapy, including: (a) Acute infectious diseases or acute active phase of chronic infection. b) Unstable angina pectoris, congestive heart failure, myocardial infarction that has been hospitalized in the past 6 months. c) Exacerbations of chronic obstructive pulmonary disease or other respiratory conditions requiring hospitalization. d) Severely impaired immune function. e) Diseases with excessive sensitivity to radiation such as ataxia telangiectasia. f) Other diseases that may affect particle radiotherapy.
- •Other circumstances that the physician considers inappropriate to participate in clinical study.
结局指标
主要结局
disease progression-free survival rate
时间窗: From date of radiotherapy started until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
disease progression-free survival rate was defined from the start of carbon ion radiotherapy till the date of disease progression at any site or death, or the last follow up.
次要结局
- overall survival rate(From date of radiotherapy started until the date of death from any cause, assessed up to 100 months)
- local control rate(From date of radiotherapy started until the date of first documented local disease progression, assessed up to 100 months)
- Incidence of Treatment-induced Adverse Events [Safety and Tolerability](From date of radiotherapy started, every 3-4 months within the first 2 years, every 6 months between years 3 and 5, and annually thereafter, assessed up to 100 months)
研究者
Jian Chen
Clinical Associate Professor
Shanghai Proton and Heavy Ion Center
研究点 (1)
Loading locations...
相似试验
招募中
2 期
Carbon Ion Radiotherapy for Locally Advanced Lung Cancer in Elderly PatientsOlder PeopleNon-small Cell Lung CancerCarbon Ion RadiotherapyRadiotherapy Side EffectNCT06311981Jian Chen29
招募中
2 期
Clinical Study of Carbon Ion Radiotherapy Combined With Chemotherapy for Thymic Epithelial TumorsCarbon Ion Radiotherapy, Thymoma, Thymic Carcinoma, Radiotherapy, ChemotherapyNCT06186726Jian Chen48
招募中
不适用
Carbon Ion Radiation Therapy in the Treatment of Mucous Melanomas of the Female Lower Genital TractMalignant MelanomaGynecologic CancerNCT05478876CNAO National Center of Oncological Hadrontherapy9
未知
1 期
A phase I/II clinical trial of Carbon-ion therapy in 12 fractions over 3 weeks for patients with carcinoma of kidneyRenal CancerJPRN-UMIN000008777ational Institute of Radiological Sciences10
已完成
1 期
A phase I/II clinical trial of carbon-ion therapy for patients with clinical stage I squamous cell carcinoma of the thoracic esophagusEsophageal cancerJPRN-UMIN000013552ational Institutes for Quantum and Radiological Science and Technology National Institute of Radiological Sciences20